FY2027 to pursue an ambitious plan for continued revenue and profit growth

Consolidated revenue for FY2026 was ¥145.419 billion, up 21.2% year on year, while operating profit was ¥45.218 billion, up 50.3%. The operating margin rose to 31.1%, a substantial improvement from approximately 25.1% a year earlier. Both the Medical and Device businesses recorded revenue growth, while higher revenue and an improved gross margin supported company-wide profit growth.

The company's FY2027 plan calls for revenue of ¥161.794 billion, operating profit of ¥52.127 billion, ordinary profit of ¥52.6 billion, net income attributable to owners of the parent of ¥37.832 billion, and EPS of ¥142.59. Compared with FY2026 results, the plan assumes growth of approximately 11.3% in revenue, 15.3% in operating profit, and 17.9% in net income, with profit growth outpacing revenue growth. The planned operating margin is approximately 32.2%, implying a further improvement of approximately 1.1 percentage points from the 31.1% achieved in FY2026.

According to the earnings presentation, FY2026 results exceeded the revised plan by ¥4.277 billion in revenue and ¥2.998 billion in operating profit. In addition, the FY2030 targets under Building the Future 2030 have been raised from revenue of ¥180.0 billion and an operating margin of 28% to revenue of ¥212.5 billion and an operating margin of 32.0%. At the next earnings announcement, we will assess not only whether year-on-year growth remains positive, but also whether the growth rate and margin required to achieve the full-year plan are being maintained against FY2026-Q1 revenue of ¥36.058 billion and operating profit of ¥13.035 billion.

Although the earnings presentation provides the full-year plan, it does not specify the first-quarter progress rate against the plan or the revenue and profit required over the remaining period. Accordingly, at the next earnings announcement we need to review the first-quarter results, whether the full-year forecast is maintained or revised, any changes to the foreign-exchange assumptions, and whether the FY2030 targets are reaffirmed.